| Autor: |
Peckert-Maier K; Department of Immune Modulation, Universitätsklinikum Erlangen, Friedrich-Alexander Universität-Erlangen-Nürnberg, 91052 Erlangen, Germany., Royzman D; Department of Immune Modulation, Universitätsklinikum Erlangen, Friedrich-Alexander Universität-Erlangen-Nürnberg, 91052 Erlangen, Germany., Langguth P; Department of Immune Modulation, Universitätsklinikum Erlangen, Friedrich-Alexander Universität-Erlangen-Nürnberg, 91052 Erlangen, Germany., Marosan A; Department of Immune Modulation, Universitätsklinikum Erlangen, Friedrich-Alexander Universität-Erlangen-Nürnberg, 91052 Erlangen, Germany., Strack A; Department of Immune Modulation, Universitätsklinikum Erlangen, Friedrich-Alexander Universität-Erlangen-Nürnberg, 91052 Erlangen, Germany., Sadeghi Shermeh A; Department of Immune Modulation, Universitätsklinikum Erlangen, Friedrich-Alexander Universität-Erlangen-Nürnberg, 91052 Erlangen, Germany., Steinkasserer A; Department of Immune Modulation, Universitätsklinikum Erlangen, Friedrich-Alexander Universität-Erlangen-Nürnberg, 91052 Erlangen, Germany., Zinser E; Department of Immune Modulation, Universitätsklinikum Erlangen, Friedrich-Alexander Universität-Erlangen-Nürnberg, 91052 Erlangen, Germany., Wild AB; Department of Immune Modulation, Universitätsklinikum Erlangen, Friedrich-Alexander Universität-Erlangen-Nürnberg, 91052 Erlangen, Germany. |
| Abstrakt: |
Chronic inflammatory diseases and transplant rejection represent major challenges for modern health care. Thus, identification of immune checkpoints that contribute to resolution of inflammation is key to developing novel therapeutic agents for those conditions. In recent years, the CD83 (cluster of differentiation 83) protein has emerged as an interesting potential candidate for such a "pro-resolution" therapy. This molecule occurs in a membrane-bound and a soluble isoform (mCD83 and sCD83, respectively), both of which are involved in resolution of inflammation. Originally described as a maturation marker on dendritic cells (DCs), mCD83 is also expressed by activated B and T cells as well as regulatory T cells (Tregs) and controls turnover of MHC II molecules in the thymus, and thereby positive selection of CD4 + T cells. Additionally, it serves to confine overshooting (auto-)immune responses. Consequently, animals with a conditional deletion of CD83 in DCs or regulatory T cells suffer from impaired resolution of inflammation. Pro-resolving effects of sCD83 became evident in pre-clinical autoimmune and transplantation models, where application of sCD83 reduced disease symptoms and enhanced allograft survival, respectively. Here, we summarize recent advances regarding CD83-mediated resolution of inflammatory responses, its binding partners as well as induced signaling pathways, and emphasize its therapeutic potential for future clinical trials. |
